Efficacy of two artemisinin combination therapies for uncomplicated falciparum malaria in children under 5 years, Malakal, Upper Nile, Sudan

<p>Abstract</p> <p>Background</p> <p>The treatment for <it>Plasmodium falciparum </it>malaria in Sudan has been in process of change since 2003. Preceding the change, this study aimed to determine which artemisinin-based combination therapies is more effecti...

Full description

Bibliographic Details
Main Authors: Alemu Engudaye, Hepple Pamela, Balasegaram Manica, Amsalu Ribka, van den Broek Ingrid, Hussein El Badri, Al-Faith Muhammed, Montgomery Jacqui, Checchi Francesco
Format: Article
Language:English
Published: BMC 2005-02-01
Series:Malaria Journal
Online Access:http://www.malariajournal.com/content/4/1/14
Description
Summary:<p>Abstract</p> <p>Background</p> <p>The treatment for <it>Plasmodium falciparum </it>malaria in Sudan has been in process of change since 2003. Preceding the change, this study aimed to determine which artemisinin-based combination therapies is more effective to treat uncomplicated malaria in Malakal, Upper Nile, Sudan.</p> <p>Methods</p> <p>Clinical trial to assess the efficacy of 2 antimalarial therapies to treat <it>P. falciparum </it>infections in children aged 6–59 months, in a period of 42 days after treatment.</p> <p>Results</p> <p>A total of 269 children were followed up to 42 days. Artesunate plus Sulfadoxine/Pyrimethamine (AS+SP) and Artesunate plus Amodiaquine (AS+AQ) were both found to be efficacious in curing malaria infections by rapid elimination of parasites and clearance of fever, in preventing recrudescence and suppressing gametocytaemia. The combination of AS+SP appeared slightly more efficacious than AS+AQ, with 4.4% (4/116) versus 15% (17/113) of patients returning with malaria during the 6-week period after treatment (RR = 0.9, 95% CI 0.81–0.96). PCR analysis identified only one recrudescence which, together with one other early treatment failure, gave efficacy rates of 99.0% for AS+AQ (96/97) and 99.1% for AS+SP (112/113). However, PCR results were incomplete and assuming part of the indeterminate samples were recrudescent infections leads to an estimated efficacy ranging 97–98% for AS+SP and 88–95% for AS+AQ.</p> <p>Conclusion</p> <p>These results lead to the recommendation of ACT, and specifically AS+SP, for the treatment of uncomplicated falciparum malaria in this area of Sudan. When implemented, ACT efficacy should be monitored in sentinel sites representing different areas of the country.</p>
ISSN:1475-2875